Novo Nordisk A/S (NYSE:NVO) Shares Sold by Surience Private Wealth LLC

Surience Private Wealth LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 92.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,050 shares of the company’s stock after selling 25,929 shares during the quarter. Novo Nordisk A/S comprises 0.2% of Surience Private Wealth LLC’s portfolio, making the stock its 27th largest holding. Surience Private Wealth LLC’s holdings in Novo Nordisk A/S were worth $244,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of NVO. Advisor OS LLC boosted its holdings in Novo Nordisk A/S by 0.6% during the second quarter. Advisor OS LLC now owns 13,972 shares of the company’s stock worth $1,994,000 after buying an additional 82 shares in the last quarter. Cascade Financial Partners LLC boosted its stake in shares of Novo Nordisk A/S by 2.3% during the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company’s stock worth $543,000 after acquiring an additional 84 shares in the last quarter. Novare Capital Management LLC raised its position in shares of Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after purchasing an additional 85 shares during the period. AA Financial Advisors LLC raised its holdings in Novo Nordisk A/S by 3.2% during the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company’s stock worth $400,000 after buying an additional 86 shares during the period. Finally, Steel Grove Capital Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 2.3% during the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after acquiring an additional 86 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Down 1.1 %

NYSE NVO traded down $1.27 on Tuesday, reaching $116.06. The stock had a trading volume of 1,475,328 shares, compared to its average volume of 4,274,455. Novo Nordisk A/S has a 1 year low of $92.94 and a 1 year high of $148.15. The business has a 50 day moving average price of $128.23 and a 200 day moving average price of $131.67. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $520.82 billion, a price-to-earnings ratio of 40.02, a P/E/G ratio of 1.56 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). The firm had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. On average, analysts forecast that Novo Nordisk A/S will post 3.01 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 16th were paid a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S’s payout ratio is presently 24.83%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 9th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.